Cancers,
Год журнала:
2022,
Номер
14(3), С. 482 - 482
Опубликована: Янв. 18, 2022
Triple-negative
breast
cancer
(TNBC)
is
a
highly
aggressive
form
of
cancer.
Due
to
its
heterogeneity
and
lack
hormone
receptor
expression,
this
subtype
more
likely
metastasize
resist
treatment
attempts
than
are
other
forms
the
absence
targetable
receptors,
chemotherapy
conserving
surgery
have
been
predominant
options
for
patients.
However,
resistance
local
recurrence
tumors
frequent.
Emerging
immunotherapies
begun
change
plans
patients
diagnosed
with
TNBC.
In
review,
we
discuss
various
immune
pathways
identified
in
TNBC
role
they
play
as
targets
new
potential
choices.
Various
therapeutic
that
inhibit
key
cellular
growth
cycles,
DNA
repair
mechanisms,
epithelial
mesenchymal
transition,
immunosuppression
shown
improve
survival
disease.
With
promising
results
thus
far,
continued
studies
immunotherapy
neoadjuvant
therapy
alter
course
these
diagnoses
future.
Human Vaccines & Immunotherapeutics,
Год журнала:
2024,
Номер
20(1)
Опубликована: Апрель 2, 2024
Breast
cancer
is
the
leading
cause
of
cancer-related
death
among
women
globally.
Immunotherapy
has
emerged
as
a
major
milestone
in
contemporary
oncology.
This
study
aims
to
conduct
bibliometric
analysis
field
immunotherapy
for
breast
cancer,
providing
comprehensive
overview
current
research
status,
identifying
trends
and
hotspots
topics.
We
searched
retrieved
data
from
Web
Science
Core
Collection,
performed
publications
on
2013
2022.
Current
status
were
evaluated
by
co-occurrence
using
VOSviewer.
Evolution
bursts
knowledge
base
assessed
co-citation
CiteSpace.
Thematic
evolution
bibliometrix
package
was
used
discover
keywords
trends.
The
attribution
collaboration
countries/regions,
institutions
authors
also
explored.
A
total
7,975
included.
In
keywords,
6
clusters
revealed:
tumor
microenvironment,
prognosis
biomarker,
immune
checkpoints,
novel
drug
delivery
methods,
cells
therapeutic
approaches.
top
three
most
frequently
mentioned
triple-negative
programmed
cell
ligand
1.
productive
country,
institution
author
USA
(2926
publications),
University
Texas
MD
Anderson
Cancer
Center
(219
Sherene
Loi
(28
respectively.
There
been
rapid
growth
studies
worldwide.
area
gained
increasing
attention
different
countries
institutions.
With
rising
incidence
represents
significant
clinical
value
potential.
Nature Communications,
Год журнала:
2020,
Номер
11(1)
Опубликована: Июль 30, 2020
Abstract
Most
triple-negative
breast
cancer
(TNBC)
patients
fail
to
respond
T
cell-mediated
immunotherapies.
Unfortunately,
the
molecular
determinants
are
still
poorly
understood.
Breast
is
disease
genetically
linked
a
deficiency
in
autophagy.
Here,
we
show
that
autophagy
defects
TNBC
cells
inhibit
tumour
killing
vitro
and
vivo.
Mechanistically,
identify
Tenascin-C
as
candidate
for
deficiency-mediated
immunosuppression,
which
Lys63-ubiquitinated
by
Skp2,
particularly
at
Lys942
Lys1882,
thus
promoting
its
recognition
p62
leading
selective
autophagic
degradation.
High
expression
associated
with
poor
prognosis
inversely
correlated
LC3B
CD8
+
patients.
More
importantly,
inhibition
of
autophagy-impaired
sensitizes
improves
antitumour
effects
single
anti-PD1/PDL1
therapy.
Our
results
provide
potential
strategy
targeting
combination
blockade
immune
checkpoint
inhibitors.
Frontiers in Oncology,
Год журнала:
2021,
Номер
11
Опубликована: Окт. 28, 2021
Triple-negative
breast
cancer
(TNBC)
is
the
most
aggressive
subtype
of
cancer,
which
characterized
by
absence
estrogen
receptor
(ER)
and
progesterone
(PR)
expression
human
epidermal
growth
factor
2
(HER2)
expression/amplification.
Conventional
chemotherapy
mainstay
systemic
treatment
for
TNBC.
However,
lack
molecular
targeted
therapies
poor
prognosis
TNBC
patients
have
prompted
a
great
effort
to
discover
effective
targets
improving
clinical
outcomes.
For
now,
poly
(ADP-ribose)
polymerase
(PARP)
inhibitors
(PARPi’s)
immune
checkpoint
been
approved
Moreover,
agents
that
target
signal
transduction,
angiogenesis,
epigenetic
modifications,
cell
cycle
are
under
active
preclinical
or
investigations.
In
this
review,
we
highlight
current
major
developments
in
TNBC,
with
some
descriptions
about
their
(dis)advantages
future
perspectives.
Expert Opinion on Investigational Drugs,
Год журнала:
2021,
Номер
31(6), С. 557 - 565
Опубликована: Ноя. 22, 2021
Introduction
Immune
checkpoint
inhibitor
(ICI)
monotherapy
appears
to
be
effective
in
a
small
cohort
of
patients
with
metastatic
triple
negative
breast
cancer
(mTNBC).
This
supports
the
exploration
strategies
for
increasing
efficacy
immunotherapy.
To
enhance
overall
response
and
clinical
outcomes,
several
immune-based
combinations
are
being
investigated.Areas
covered
The
authors
present
synopsis
current,
state-of-art
this
setting
reflect
on
future
possibilities.
They
shed
light
recently
presented
published
trials
ongoing
studies.
A
literature
search
was
conducted
October
2021;
addition,
abstracts
international
meetings
were
reviewed.Expert
opinion
Clinical
suggest
that
ICI
could
beneficial
minority
mTNBC
patients;
conversely,
have
reported
notable
results
or
Some
these
combination
been
approved
–
as
case
chemoimmunotherapy
PD-L1
positive
patients.
Numerous
investigating
novel
ICI-based
their
eagerly
awaited.
Breast
cancer
is
the
most
prevalent
in
women
worldwide.
Triple‑negative
breast
(TNBC)
characterized
by
lack
of
expression
estrogen
receptor,
progesterone
and
human
epidermal
growth
factor
receptor
2.
It
aggressive
subtype
accounts
for
12‑20%
all
cases.
TNBC
associated
with
younger
age
onset,
greater
metastatic
potential,
higher
incidence
relapse,
lower
overall
survival
rates.
Based
on
molecular
phenotype,
has
been
classified
into
six
subtypes
(BL1,
BL2,
M,
MES,
LAR,
IM).
treatment
challenging
due
to
its
heterogeneity,
highly
invasive
nature,
relatively
poor
therapeutics
response.
Chemotherapy
radiotherapy
are
conventional
strategies
TNBC.
Recent
research
mechanistic
understanding
disease
pathogenesis
using
cutting‑edge
technologies
led
unfolding
new
lines
therapies
that
have
incorporated
clinical
practice.
Poly
(ADP‑ribose)
polymerase
immune
checkpoint
inhibitors
made
their
way
current
paradigm.
This
review
focuses
classification,
features,
progress
Histological
connected
recurrence,
classification
TNBC,
targeted
therapy
early
advanced
advances
non‑coding
RNA
key
highlights
this
review.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(23), С. 14937 - 14937
Опубликована: Ноя. 29, 2022
Heterogeneity
of
triple-negative
breast
cancer
is
well
known
at
clinical,
histopathological,
and
molecular
levels.
Genomic
instability
greater
mutation
rates,
which
may
result
in
the
creation
neoantigens
enhanced
immunogenicity,
are
additional
characteristics
this
type.
Clinical
outcome
poor
due
to
early
age
onset,
high
metastatic
potential,
increased
likelihood
distant
recurrence.
Consequently,
efforts
elucidate
mechanisms
development,
progression,
spread
have
been
initiated
improve
treatment
options
outcomes
for
these
patients.
The
extremely
complex
heterogeneous
tumor
immune
microenvironment
made
up
several
cell
types
commonly
possesses
disorganized
gene
expression.
Altered
signaling
pathways
mainly
associated
with
mutated
genes
including
p53,
PIK3CA,
MAPK,
positively
correlated
regulating
response.
Of
note,
particular
immunity-associated
could
be
used
prognostic
indexes
assess
most
effective
management.
Recent
findings
highlight
fact
that
long
non-coding
RNAs
also
play
an
important
role
shaping
formation,
can
mediate
evasion.
Identification
signatures,
through
use
multi-omics
approaches,
effector
drive
stages
carcinogenic
process
steps
developing
new
strategies
targeted
prevention.
Advances
immunotherapy
by
remodeling
host
system
eradicate
cells
great
promise
lead
novel
therapeutic
strategies.
Current
research
focused
on
combining
checkpoint
inhibition
chemotherapy,
PARP
inhibitors,
vaccines,
or
natural
killer
therapy.
Targeted
therapies
response,
eliminate
resistance,
overall
patient
survival.
In
future,
evolving
advancements
should
implemented
personalized
medicine
state-of-art
management
Bioactive Materials,
Год журнала:
2022,
Номер
20, С. 548 - 560
Опубликована: Июнь 29, 2022
Bacterial
outer
membrane
vesicles
(OMVs)
are
potent
immuno-stimulating
agents
and
have
the
potentials
to
be
bioengineered
as
platforms
for
antitumor
nanomedicine.
In
this
study,
OMVs
demonstrated
promising
therapeutics.
can
lead
beneficial
M2-to-M1
polarization
of
macrophages
induce
pyroptosis
enhance
immunity,
but
therapeutic
window
is
narrow
its
toxicity.
We
propose
a
bioengineering
strategy
tumor-targeting
ability
by
macrophage-mediated
delivery
improve
efficacy
co-loading
photosensitizer
chlorin
e6
(Ce6)
chemotherapeutic
drug
doxorubicin
(DOX)
into
platform.
demonstrate
that
systemic
injection
DOX/Ce6-OMVs@M
platform,
providing
combinational
photodynamic/chemo-/immunotherapy,
eradicates
triple-negative
breast
tumors
in
mice
without
side
effects.
Importantly,
also
effectively
prevents
tumor
metastasis
lung.
This
OMVs-based
with
may
serve
powerful
platform
synergic
therapy.
Journal of Nanobiotechnology,
Год журнала:
2021,
Номер
19(1)
Опубликована: Май 19, 2021
Abstract
Background
Triple
negative
breast
cancer
(TNBC)
is
an
aggressive
tumor
with
extremely
high
mortality
that
results
from
its
lack
of
effective
therapeutic
targets.
As
adhesion
molecule
related
to
tumorigenesis
and
metastasis,
cluster
differentiation-44
(also
known
as
CD44)
overexpressed
in
TNBC.
Moreover,
CD44
can
be
effectively
targeted
by
a
specific
hyaluronic
acid
analog,
namely,
chitosan
oligosaccharide
(CO).
In
this
study,
CO-coated
liposome
was
designed,
Photochlor
(HPPH)
the
660
nm
light
mediated
photosensitizer
evofosfamide
TH302)
hypoxia-activated
prodrug.
The
obtained
liposomes
help
diagnose
TNBC
fluorescence
imaging
produce
antitumor
therapy
synergetic
photodynamic
(PDT)
chemotherapy.
Results
Compared
nontargeted
liposomes,
exhibited
good
biocompatibility
targeting
capability
vitro;
vivo,
much
better
capability.
Additionally,
loaded
HPPH
TH302
showed
significantly
effects
than
other
monotherapy
groups
both
vitro
vivo.
Conclusion
impressive
synergistic
effects,
together
superior
capability,
minor
side
confers
potential
for
future
translational
research
diagnosis
CD44-overexpressing
therapy,
especially
Graphic
abstract
Future Oncology,
Год журнала:
2022,
Номер
18(18), С. 2301 - 2309
Опубликована: Апрель 5, 2022
Stage
I-III
triple-negative
breast
cancer
accounts
for
approximately
15-20%
of
new
diagnoses
early
cancer.
Novel
systemic
treatment
options
have
recently
been
assessed
as
part
the
neoadjuvant
approach,
such
addition
immune
checkpoint
inhibitors
to
cytotoxic
chemotherapy.
However,
several
questions
remain
unanswered,
including
identification
predictors
response
immunotherapy
in
this
setting,
and
further
efforts
aimed
at
identifying
reliable
clarifying
effective
role
PD-L1
status,
tumor
mutational
burden,
tumor-infiltrating
lymphocytes
other
biomarkers
are
warranted.
Herein
we
will
provide
an
overview
recent
clinical
studies
patients
with
cancer,
especially
focusing
on
presented
published
KEYNOTE-522,
IMpassion031
GeparNUEVO
trials.
BMC Bioinformatics,
Год журнала:
2022,
Номер
23(1)
Опубликована: Авг. 22, 2022
Abstract
Cuproptosis
induction
represents
a
promising
alternative
for
immunotherapies
and
targeted
therapies
in
breast
cancer.
This
study
aimed
to
investigate
the
prognostic
biological
significance
of
cuproptosis-related
genes
In
current
study,
we
examined
transcriptional
clinical
data
13
patients
with
cancer
from
TCGA
database.
We
found
that
DLAT,
SLC31A1,
ATP7A
ATP7B
were
significantly
related
overall
survival
(OS)
univariate
Cox
regression
analysis.
Unlike
lung
or
kidney
cancers,
SLC31A1
expression
was
upregulated
samples
compared
normal
tissues,
predicted
poor
prognosis.
Univariate
multivariate
analyses
indicated
high
level
an
independent
factor
shorter
OS.
A
nomogram
integrating
age,
T-,
N-stage
stage
constructed,
calibration
curves
1-,
3-,
5-,
10-year
OS
fitted
well
ideal
model.
Furthermore,
deregulated
immune
response
metabolic
pathways.
Low
sensitivity
CTLA4
inhibitors
but
paclitaxel.
Our
may
provide
novel
insights
copper
homeostasis
cuproptosis